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Diminished linear growth during intermittent calcitriol therapy in
children undergoing CCPD. Daily calcitriol therapy has been reported to
improve linear growth in children with renal bone disease, and 1,25-
dihydroxyvitamin D is a key regulator of chondrocyte proliferation and
differentiation. Whereas large intermittent doses of calcitriol can lower
serum parathyroid hormone (PTH) levels and reverse the skeletal changes
of secondary hyperparathyroidism, the impact of intermittent calcitriol
therapy on linear growth in children is not known. Thus, we studied 16
pre-pubertal patients with bone biopsy-proven secondary hyperparathy-
roidism who completed a 12-month prospective clinical trial of intermit-
tent calcitriol therapy. Biochemical results and growth data obtained
during intermittent calcitriol therapy were compared to values determined
during the preceding 12 months of daily calcitriol therapy in each study
subject; changes in bone histology were assessed after one year of
intermittent calcitriol therapy. Z-scores for height did not change during
12 months of daily calcitriol therapy. Although the skeletal lesions of
secondary hyperparathyroidism improved in most patients, Z-scores for
height decreased from 21.8 6 0.32 to 22.0 6 0.33, P , 0.01, during
intermittent calcitriol therapy. The largest reductions were seen in pa-
tients who developed adynamic bone lesions after 12 months of treatment.
Delta Z-scores for height correlated with serum PTH, r 5 0.71, P , 0.01,
and alkaline phosphatase levels, r 5 0.67, P , 0.01, during intermittent
calcitriol therapy but not during daily calcitriol therapy. The data suggest
that high dose intermittent calcitriol therapy adversely affects linear
growth, particularly in patients with the adynamic lesion. The higher doses
of calcitriol or the intermittent schedule of calcitriol administration may
directly inhibit chondrocyte activity within growth plate cartilage of
children with end-stage renal disease.
Treatment with daily doses of calcitriol, or 1,25-dihydroxyvita-
min D, has been reported to improve linear growth and to prevent
skeletal deformities in pediatric patients with renal bone disease
[1, 2]. Such findings provide the rationale for the routine admin-
istration of calcitriol to nearly all children with chronic renal
failure. Secondary hyperparathyroidism remains a persistent
problem, however, in children with advanced renal disease, and
osteitis fibrosa continues to be the most common skeletal lesion of
renal osteodystrophy in those undergoing regular dialysis despite
regular treatment with daily doses of oral calcitriol [3, 4]. Accord-
ingly, alternative therapeutic regimens have been sought to pro-
vide better control of secondary hyperparathyroidism in pediatric
patients with end-stage renal disease.
Large intermittent doses of calcitriol have recently been used to
treat secondary hyperparathyroidism both in children and in
adults [5–10]. Doses have generally been given thrice weekly by
the oral, intravenous or intraperitoneal route of administration [6,
8, 11]. Available data indicate that approximately 40% of children
currently undergoing regular hemodialysis are given calcitriol
using an intermittent dosage regimen, but the impact of this
therapeutic approach on linear growth has not been evaluated
[12].
In this regard, intermittent calcitriol therapy has been shown to
markedly reduce bone formation and to suppress osteoblastic
activity both in adults and in children [6, 8]. Direct inhibitory
effects of calcitriol on osteoblast function and/or proliferation
may be partially responsible [8]. Whether calcitriol also dimin-
ishes chondrocyte activity within growth plate cartilage remains to
be determined, but 1,25-dihydroxyvitamin D has potent anti-
proliferative actions in vitro in a variety of cell lines including
chondrocytes [13]. The current study was undertaken, therefore,
to measure linear growth during 12 months of intermittent
calcitriol therapy and to compare the results with those obtained
during the preceding year of daily oral calcitriol therapy in
pre-pubertal children with secondary hyperparathyroidism under-
going maintenance peritoneal dialysis.
METHODS
Sixteen pre-pubertal subjects were selected from a total of 35
patients who had completed a 12-month prospective, randomized
clinical trial of intermittent oral versus intermittent intraperito-
neal calcitriol for the treatment of bone biopsy-proven secondary
hyperparathyroidism. For the current study, only children who
had not entered puberty after completing the 12-month clinical
trial were included. Measurements of linear growth and monthly
biochemical data obtained during intermittent calcitriol therapy
were compared to values determined during the preceding 12
months of daily oral calcitriol therapy in each study subject. In
addition, parameters of nutritional status and the number of
peritonitis episodes, hospital admissions and total in-patient hos-
pital days were evaluated during each 12 month period of
observation.
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There were 9 female and 7 male patients, aged 10 6 1.1 (SE)
years. The average bone age was 9.5 6 1.2 years, and the duration
of maintenance dialysis prior to treatment with intermittent
calcitriol was 20 6 4.9 months. All patients received continuous
cycling peritoneal dialysis (CCPD) throughout the 24 months of
observation using standard peritoneal dialysate solutions contain-
ing 3.5 mEq/liter of calcium (Dianeal; Baxter, Deerfield, IL, USA)
[3, 8]. Calcium carbonate was used as the primary phosphate-
binding agent throughout the study, and the dose was adjusted
according to monthly measurements of serum calcium and phos-
phorus levels as previously reported [8, 14]. The dietary intake of
calcium and phosphorus was monitored each month during the 24
month period of observation using three-day diet histories [15].
All patients were treated with erythropoietin but none of the
patients received recombinant human growth hormone (rhGH)
during the 24 months of observation. All studies were approved by
the UCLA Human Subjects Protection Committee, and written
informed consent was obtained from all patients and their par-
ents.
Intermittent calcitriol therapy
During intermittent calcitriol therapy, five patients received
oral doses of calcitriol thrice weekly (Rocaltrol®; Hoffmann-
LaRoche, Nutley, NJ, USA), whereas eleven patients were given
intraperitoneal doses of calcitriol three times per week as previ-
ously described (Calcijex®; Abbott Laboratories, Abbott Park, IL,
USA) [8]. The initial dose of calcitriol during intermittent therapy
was 1.0 mg thrice weekly, and doses were adjusted monthly based
on regular measurements of serum calcium and phosphorus
levels. The dose of calcitriol was increased in increments of 0.5 mg
if serum calcium levels remained less than 10 mg/dl and if serum
phosphorus levels remained below 6.5 mg/dl. Treatment was
temporarily withheld if hypercalcemia, defined as a serum calcium
level above 11 mg/dl, or hyperphosphatemia, defined as a serum
phosphorus level greater than 7 mg/dl developed. Calcitriol
therapy was resumed after reducing the dose by 50% when serum
calcium and phosphorus levels fell below 11 mg/dl and 7 mg/dl,
respectively.
Iliac crest bone biopsies following double tetracycline labeling
were obtained before and after 12 months of intermittent calci-
triol therapy [3, 8]. As such, the bone biopsy done prior to starting
intermittent calcitriol therapy reflected the histologic state of
bone after 12 months of daily oral calcitriol therapy. The skeletal
lesions of renal osteodystrophy were classified by histomorpho-
metric criteria with reference to values established in children
with normal renal function as described previously [3, 8]. The
terminology established by the Nomenclature Committee of the
American Society for Bone and Mineral Research was used to
report all histomorphometric results [16].
Daily calcitriol therapy
All patients who entered the 12-month clinical trial of intermit-
tent calcitriol therapy had previously been treated with daily oral
doses of calcitriol for at least one year. Monthly measurements of
height and monthly biochemical determinations obtained during
daily oral calcitriol therapy were retrospectively evaluated, and
the results compared to those obtained during intermittent calci-
triol therapy. During daily calcitriol therapy, the initial dose of
calcitriol was 0.25 to 0.5 mg, and doses were increased by 0.25 to
0.5 mg based upon regular measurements of serum calcium and
phosphorus levels. The same biochemical criteria described pre-
viously for intermittent calcitriol therapy were used to guide
dosage adjustments during daily therapy.
The average daily dose of calcitriol for each 12-month treat-
ment interval was calculated by dividing the weekly cumulative
dose by seven. Values were expressed in mg/day or in ng/kg body
wt per day.
Assessments of growth and skeletal maturity
Standing heights were measured monthly by the same dietitian
using a fixed, wall-mounted stadiometer. All height measurements
were repeated until three consecutive values agreed within 0.2 cm.
For statistical evaluation, height measurements were expressed as
standard deviation (SD) scores, or Z-scores, relative to values
corresponding to the 50th percentile of the population norm for
children of the same age and gender according to tables provided
by the National Center for Health Statistics, Hyattsville, Maryland
[17]. Delta Z-scores for height were calculated from values
obtained before and after each 12 month period of observation.
Skeletal maturity was determined using radiographs of the hand
and wrist at the start of intermittent calcitriol therapy. Bone age
was assessed by an independent observer using the method of
Greulich and Pyle [18].
Hematological and biochemical determinations
Determinations of hematocrit and of total CO2, total protein,
albumin, calcium, phosphorus, alkaline phosphatase and PTH
levels in serum were done as previously described [3, 8, 19]. Serum
PTH levels were measured using an immunoradiometric assay for
the intact hormone (Allegro PTH; Corning-Nichols, San Juan
Capistrano, CA, USA) [19]. The reference range for subjects with
normal renal function using this assay is 10 to 65 pg/ml.
Statistical analysis
All results are expressed as means 6 standard error. Statistical
analysis of the data were done using paired t-tests, one-way
analysis of variance with contrasts, analysis of variance for re-
peated measures and chi-square analysis. Linear regression anal-
ysis was done by the method of least squares.
RESULTS
Biochemical and histologic results
All patients were clinically stable throughout the 24 months of
observation, and none was withdrawn from study or lost to
Table 1. Indices of nutrition and morbidity during daily and
intermittent calcitriol therapy
Variable Daily Intermittent
Hematocrit % 28.1 6 0.8 31.2 6 0.6a
Serum total CO2 mmol/liter 23.3 6 0.6 23.8 6 0.6
Serum total protein g/dl 6.3 6 0.2 6.4 6 0.1
Serum albumin g/dl 3.7 6 0.1 3.8 6 0.1
Peritonitis #/patient-year 0.8 6 0.3 0.8 6 0.2
Hospital admissions #/patient-year 1.3 6 0.3 1.6 6 0.4
In-patient hospital days #/patient-year 8.1 6 2.2 9.2 6 4.0
Values are means 6 SE. Individual values represent the average of 12
monthly determinations during each treatment period.
a P , 0.01
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follow-up. The number of hospital admissions, total in-patient
hospital days and peritonitis rates did not differ between the two
treatment intervals (Table 1). In addition, there were no differ-
ences in the serum levels of total CO2, total protein or albumin
between daily and intermittent calcitriol therapy. Hematocrit
values were slightly higher, however, during intermittent calcitriol
therapy (Table 1).
Serum PTH levels were 550 6 111 pg/ml at the start of
intermittent calcitriol therapy, values consistent with the histo-
logic severity of secondary hyperparathyroidism documented by
bone biopsy. Accordingly, nine of 16 patients had osteitis fibrosa,
whereas seven had mild lesions of secondary hyperparathyroidism
(Fig. 1). After 12 months of intermittent calcitriol therapy, four
patients had persistent changes of osteitis fibrosa, but the rate of
bone formation and the extent of marrow and/or peri-trabecular
fibrosis had decreased in each (Fig. 1). Three patients with initial
lesions of overt osteitis fibrosa had mild lesions of secondary
hyperparathyroidism on repeat bone biopsy, whereas two with
mild secondary hyperparathyroidism developed osteitis fibrosa.
Of the remaining patients, three had normal rates of bone
formation on follow-up bone biopsy, whereas four patients, or
25% of subjects, developed adynamic lesions of renal osteodys-
trophy (Fig. 1). Overall, bone formation decreased from 1091 6
132 to 548 6 143 mm2/mm2/day during intermittent calcitriol
therapy (P , 0.01) and 9/16 patients had bone formation rates
that fell within or below the range of normal for healthy subjects
of the same age.
Despite histologic improvement, serum PTH levels remained
elevated during treatment with intermittent doses of calcitriol,
and values did not change from baseline levels during the
subsequent 12 months (Fig. 2). Serum PTH levels were also
persistently elevated during daily calcitriol therapy in all patients,
and there was no overall difference in serum PTH levels between
the two 12-month periods of observation (Fig. 2); monthly PTH
values averaged 520 6 109 pg/ml during intermittent calcitriol
therapy and 553 6 101 pg/liter during daily calcitriol therapy (P 5
NS).
Serum PTH levels were substantially lower, however, in subjects
who developed adynamic lesions during intermittent calcitriol
therapy (Fig. 2). In this subgroup of patients, serum PTH levels
were 254 6 108 pg/ml before treatment, but values decreased
after the second month to levels that were often less that 100
pg/ml. In contrast, serum PTH levels at the beginning of treatment
were 697 6 134 pg/ml in patients who did not develop adynamic
lesions of bone, and values generally remained above 400 pg/ml,
ranging from 390 and 850 pg/ml. Serum PTH levels averaged over
the full 12 months of treatment were 100 6 30 pg/ml in those who
developed adynamic lesions and 660 6 120 pg/ml in those who did
not have adynamic bone at the time of repeat bone biopsy (P ,
0.001).
Serum alkaline phosphatase levels were moderately higher
before starting intermittent calcitriol therapy, 388 6 62 IU/liter,
than before treatment with daily doses of calcitriol, 328 6 61
IU/liter (P , 0.001; Fig. 2). Values averaged over the full 12
months of treatment were lower, however, during intermittent,
299 6 35 IU/liter, than during daily calcitriol therapy, 334 6 39
IU/liter (P , 0.01). Alkaline phosphatase levels decreased after
the first month of intermittent therapy, and values at each
monthly interval thereafter remained below baseline levels except
during the final month of observation. These changes corre-
sponded to marked reductions in bone formation documented by
bone biopsy. In contrast, serum alkaline phosphatase levels were
Fig. 1. Bone histology before and after 12 months of intermittent calci-
triol therapy in 16 pre-pubertal children with secondary hyperparathy-
roidism. Abbreviations are: OF, osteitis fibrosa; mild, mild lesion of
secondary hyperparathyroidism; NL, normal bone formation rate; and
adynamic, adynamic renal osteodystrophy.
Fig. 2. Mean serum PTH (A) and alkaline phosphatase levels (B) during
daily (F, N 5 16) and intermittent (f, N 5 16) calcitriol therapy. Values
in four patients who developed adynamic skeletal lesions during intermit-
tent calcitriol therapy are shown separately (). Values are means 6 SE.
Overall, serum alkaline phosphatase levels were lower during intermittent
therapy than during daily therapy, *P , 0.01 by analysis of variance for
repeated measures. During intermittent calcitriol therapy, serum PTH and
alkaline phosphatase values were lower in those who developed adynamic
lesions than in subjects who did not have adynamic bone after 12 months
of treatment, **P , 0.001.
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persistently elevated throughout the 12 months of daily calcitriol
therapy, results consistent with bone biopsy evidence of overt
secondary hyperparathyroidism in all subjects at the time they
were switched to intermittent calcitriol therapy (Fig. 2).
Baseline serum alkaline phosphatase levels were lower in
patients who developed adynamic lesions, 226 6 42 IU/liter, than
in those who had normal or increased rates of bone formation,
442 6 77 IU/liter, during intermittent calcitriol therapy (Fig. 2).
Similarly, values averaged over the full 12 months of treatment
were 157 6 34 and 347 6 35 IU/liter, respectively, in these two
subgroups of patients (P , 0.001).
Serum calcium levels did not differ at the start of each
treatment interval. Values were 9.6 6 0.24 mg/dl before daily and
9.4 6 0.33 mg/dl before intermittent therapy (P 5 NS). Serum
calcium levels were greater, however, when values were averaged
over the full 12 months of treatment with intermittent doses of
calcitriol, 9.8 6 0.24 versus 9.3 6 0.28 mg/dl (P , 0.05), despite
similar levels of dietary calcium intake. The average dietary
calcium intake was 350 6 41 mg/day during daily and 433 6 26
mg/day during intermittent calcitriol therapy (P 5 NS). For each
treatment interval of 192 patient-months, seventeen episodes of
hypercalcemia were documented in eight patients given intermit-
tent doses of calcitriol, whereas six episodes of hypercalcemia
were observed in four patients receiving daily calcitriol (x2 5 5.6,
P , 0.025).
Baseline serum phosphorus levels also did not differ before
treatment with intermittent or daily doses of calcitriol; values
were 6.2 6 0.44 and 6.2 6 0.35 mg/dl, respectively. Despite
equivalent levels of dietary phosphorus intake during intermittent,
740 6 59 mg/day, and daily calcitriol therapy, 703 6 60 mg/day (P
5 NS), serum phosphorus levels were greater during intermittent
therapy, 6.4 6 0.24 versus 6.1 6 0.22 mg/dl (P , 0.05), when
monthly values were averaged over each 12 months of observa-
tion. Overt hyperphosphatemia was more frequent during inter-
mittent calcitriol therapy. There were 63 and 44 episodes of
hyperphosphatemia during each 192 patient-months of treatment
with intermittent and daily doses of calcitriol, respectively (x2 5
5.78, P , 0.025).
The average daily dose of calcitriol was 1.18 6 0.21 mg or 38.1 6
5.4 ng/kg during intermittent calcitriol therapy and 0.45 6 0.15 mg
or 15.1 6 3.5 ng/kg during daily therapy (P , 0.01). The dose of
calcitriol did not differ, however, between patients who developed
adynamic lesions and those who had normal or persistently
elevated rates of bone formation after intermittent calcitriol
therapy. Values were 1.01 6 0.12 mg or 34.5 6 2.9 ng/kg and
1.23 6 0.27 mg or 39.2 6 7.2 ng/kg, respectively, in these two
subgroups (P 5 NS).
Assessments of growth
The mean Z-score for height at the start of each treatment
interval did not differ, and values did not change during treatment
with daily doses of calcitriol (Fig. 3). In contrast, Z-scores for
height decreased from 21.8 6 0.32 to 22.0 6 0.33 (P , 0.01),
after 12 months of intermittent calcitriol therapy (Fig. 3). The
largest decline was seen in subjects who developed adynamic
lesions of bone (Fig. 3). Individual delta Z-scores for height
during intermittent calcitriol therapy correlated with the serum
levels of PTH (r 5 0.71, P , 0.01) and alkaline phosphatase (r 5
0.67, P , 0.01) when the latter values were averaged over the full
12 months of treatment (Fig. 4). Similar relationships could not be
documented, however, during daily calcitriol therapy; thus, delta
Z-scores for height did not correspond to either serum PTH (r 5
20.38, NS) or alkaline phosphatase levels (r 5 0.30, NS) during
daily calcitriol therapy.
DISCUSSION
The results of the current study indicate that high dose inter-
mittent calcitriol therapy adversely affects linear growth in pre-
pubertal children with chronic renal failure undergoing mainte-
nance peritoneal dialysis. Linear growth during intermittent
calcitriol therapy was less than during the preceding 12 months of
daily calcitriol as judged by reductions in Z-scores for height in the
same study subjects. Other factors which can adversely affect
growth in children with advanced renal disease such as malnutri-
tion, metabolic acidosis, anemia and intercurrent illnesses are
unlikely to account for this finding. Thus, the serum levels of
albumin, total protein and total CO2 did not differ between
treatment regimens, and hematocrit values were actually higher
during intermittent calcitriol therapy. Also, the number of epi-
sodes of peritonitis, the number of hospital admissions and total
number of in-patient hospital days during each treatment interval
Fig. 3. Z-scores for height (A) in 16 pre-pubertal children with secondary
hyperparathyroidism before and after each 12 months treatment interval,
*P < 0.01 versus 12 months. The change in Z-scores for height during
intermittent calcitriol (B) in patients who developed adynamic lesions of
bone (f, N 5 4) and in those with normal or persistently high bone
formation rates (o, N 5 12) on follow-up evaluation, **P , 0.001.
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did not differ. The moderately higher serum calcium and phos-
phorus levels during intermittent therapy most probably reflect
the larger average weekly dose of 1,25-dihydroxyvitamin D, but
these changes were not associated with alterations in other
nutritional indices. Such findings suggest that either the higher
weekly dose of calcitriol delivered during intermittent therapy or
the intermittent schedule of calcitriol administration adversely
affects the chondrocyte activity within the growth plate of pre-
pubertal children with end-stage renal disease.
The extent of growth retardation for subjects enrolled in the
current study was characteristic of children undergoing regular
peritoneal dialysis [12]. Z-scores for height were 21.72 6 0.34 at
the start of daily calcitriol therapy, and values did not change
during the ensuing 12 months. In contrast, Z-scores for height
decreased from 21.8 to 22.0, or by 10%, during intermittent
calcitriol therapy, and the greatest reductions were seen in
patients with adynamic lesions of renal osteodystrophy after 12
months of treatment. The results suggest that the risk of further
growth retardation in children with chronic renal failure is
greatest in patients who develop adynamic bone during intermit-
tent calcitriol therapy.
Although calcitriol has been shown to enhance linear growth in
rats with renal failure [20], clinical studies have not consistently
demonstrated such a response [21–23]. Chesney et al [1] and
Chan, Kodroff and Landwehr [2] reported increases in growth
velocity during daily calcitriol therapy at doses ranging from 15 to
40 ng/kg/day in small numbers of children with stable chronic
renal failure and in those undergoing regular dialysis. The severity
of bone disease before treatment was quite advanced, however, in
these early studies, and sustained increases in growth velocity
could not be documented on long-term follow-up [24]. In subse-
quent studies, the administration of similar doses of daily oral
calcitriol to children with renal failure failed to enhance linear
growth [21–23]. The results for growth during the current 12
months study using equivalent doses of daily oral calcitriol agree,
therefore, with several previous reports [21–23].
The reductions in growth observed during intermittent calcitriol
therapy in the current clinical study are also consistent with the
results of recent studies in experimental animals, which suggest
that intermittent rather than continuous calcitriol administration
adversely affects linear growth. Berger et al reported slower
growth in rats given intermittent doses of calcitriol compared to
animals given equivalent weekly doses of 1,25-dihydroxyvitamin D
delivered continuously by mini-osmotic pump [25]. A similar
disparity in linear growth was seen between intermittent and
continuous calcitriol dosage regimens in animals receiving recom-
binant human growth hormone (rhGH) [25], and preliminary
studies suggest that calcitriol blunts the expected increase in
growth plate thickness during rhGH therapy in rats with renal
failure [26]. Inhibitory effects of calcitriol on chondrocyte prolif-
eration have been described in a variety of in vitro studies, and
calcitriol plays an important role in regulating the rate of differ-
entiation of proliferating chondrocytes within the growth plate
[13, 27–30]. Overall, such findings suggest that the therapeutic
administration of calcitriol can directly affect epiphyseal growth
plate chondrocytes, thereby contributing to the reductions in
linear growth documented in the current study.
Endochondral bone formation is a carefully controlled process
in which PTHrP and the PTH/PTHrP receptor, together with the
developmentally important hedgehog family of secreted proteins,
interact through an autocrine/paracrine mechanism to regulate
chondrocyte differentiation [31, 32]. Both PTHrP and Indian
hedgehog (Ihh) act to delay the differentiation of proliferating
chondrocytes into hypertrophic chondrocytes; as such, mice lack-
ing both alleles of the gene for either PTHrP or the PTH/PTHrP
receptor have disproportionately shortened limbs due to an
acceleration of chondrocyte differentiation which leads to prema-
ture ossification of the cartilaginous templates of long bones [33].
In contrast, activating mutations of the PTH/PTHrP receptor such
as the one found in Jansen’s metaphyseal chondrodysplasia are
associated with a delay in the transition of proliferating chondro-
cytes into hypertrophic chondrocytes within growth plate cartilage
[34]. Similar changes occur in transgenic mice in which the
expression of PTHrP is controlled by the type II collagen pro-
moter [35]. Overall, these findings emphasize the critical role of
PTHrP and the PTH/PTHrP receptor in the regulation of chon-
drocyte differentiation and bone elongation.
In chronic renal failure, PTH/PTHrP receptor expression is
diminished in the epiphyseal growth plate of long bones [36], and
1,25-dihydroxyvitamin D lowers PTH/PTHrP receptor expression
in vitro [37]. Whether the administration of exogenous calcitriol to
children with renal failure disrupts the orderly transition of
proliferating chondrocytes into hypertrophic chondrocytes or
diminishes the rate of cell division within the zone of proliferation
within the growth plate cartilage remains to be determined.
Nevertheless, these in vitro and in vivo findings suggest that
Fig. 4. Relationship between the change in Z-score for height and serum
PTH (A; r 5 0.71; P < 0.01) and alkaline phosphatase levels (B; r 5 0.67;
P < 0.01) during intermittent calcitriol therapy. Each data point repre-
sents the mean of 12 monthly determinations of PTH or alkaline
phosphatase for an individual patient.
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alterations in the functional expression of the receptor for PTH/
PTHrP in conjunction with either direct or indirect effects of
1,25-dihydroxyvitamin D on chondrocyte differentiation contrib-
ute to abnormalities in linear growth in children with chronic
renal failure. Additional work will be required, however, to
adequately characterize the role of calcitriol as a direct modifier
of endochondral bone development.
The prevalence of adynamic renal osteodystrophy has increased
substantially both in adults and in children [8, 38, 39], and
previous work has demonstrated that this skeletal lesion can arise
after intermittent calcitriol therapy, particularly when serum PTH
and serum alkaline phosphatase levels fall substantially [8]. The
long-term consequences of this disorder remain uncertain, but
adynamic renal osteodystrophy often leads to recurrent episodes
of hypercalcemia and it may be associated with an increase in
fracture risk and with higher mortality rates in adult patients
undergoing long-term dialysis [40, 41]. The results of the current
study suggest that the adynamic lesion can also adversely affect
linear growth in pre-pubertal children undergoing peritoneal
dialysis if it develops during intermittent calcitriol therapy. As
such, oversuppression of parathyroid gland function in pre-
pubertal children undergoing regular dialysis should be avoided to
diminish the risk of aggravating the growth retardation that
characterizes this subgroup of patients.
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